JS-K
Based on 1 Customer Validation
JS-K is a NO donor that reacts with glutathione to generate NO at physiological pH. JS-K induces reactive oxygen species (ROS) to mediate apoptosis. JS-K induces autophagy. JS-K inhibits invasion. JS-K has a broad spectrum anti-proliferative activity in cancer cells. JS-K reduces tumor volume and causes necrosis of implanted tumors in mice.
For research use only. We do not sell to patients.
- Purity : 99.59%
- CAS No.: 205432-12-8
- Formula: C13H16N6O8
- Molecular Weight:384.30
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 786-0 | IC50 |
0.8 μM
Compound: JS-K
|
Antiproliferative activity against human 786O cells after 72 hrs by MTT assay
Antiproliferative activity against human 786O cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| A2780 | IC50 |
>20 μM
Compound: JS-K
|
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human A2780 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 36470106] |
| A2780 | IC50 |
0.63 μM
Compound: 19
|
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay
|
[PMID: 25350923] |
| A549 | IC50 |
0.69 μM
Compound: 6; JS-K
|
Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
|
[PMID: 32305784] |
| A549 | IC50 |
1.26 μM
Compound: 19
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 25350923] |
| A549 | IC50 |
1.5 μM
Compound: JS-K
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| A549 | IC50 |
2.11 μM
Compound: JS-K
|
Anticancer activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
Anticancer activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
|
[PMID: 32156499] |
| A549 | IC50 |
2.313 μM
Compound: JS-K
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 29501947] |
| A549 | IC50 |
6.53 μM
Compound: JS-K
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay relative to control
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay relative to control
|
[PMID: 29220794] |
| A549/TR | IC50 |
1.987 μM
Compound: JS-K
|
Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay
Antiproliferative activity against human A549/TR cells after 72 hrs by MTT assay
|
[PMID: 29501947] |
| B16 | IC50 |
1340 nM
Compound: 1; JS-K
|
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
Antiproliferative activity against mouse B16 cells after 72 hrs by MTT assay
|
[PMID: 29420887] |
| Bel-7402 | IC50 |
5.17 μM
Compound: JS-K
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 23617697] |
| BT-474 | IC50 |
3.66 μM
Compound: JS-K
|
Anticancer activity against human BT474 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
Anticancer activity against human BT474 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
|
[PMID: 32156499] |
| Caco-2 | IC50 |
2.6 μM
Compound: JS-K
|
Antiproliferative activity against human Caco-2 cells after 72 hrs by MTT assay
Antiproliferative activity against human Caco-2 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| CCRF-CEM | IC50 |
0.89 μM
Compound: JS-K
|
Anticancer activity against human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
Anticancer activity against human CCRF-CEM cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
|
[PMID: 32156499] |
| ES-2 | IC50 |
>20 μM
Compound: JS-K
|
Antiproliferative activity against human ES2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human ES2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 36470106] |
| HCT-116 | IC50 |
0.5 μM
Compound: 6; JS-K
|
Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
|
[PMID: 32305784] |
| HCT-116 | IC50 |
0.7 μM
Compound: JS-K
|
Antiproliferative activity against human HCT 116 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT 116 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| HCT-116 | IC50 |
3.75 μM
Compound: JS-K
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| HCT-116 | IC50 |
4.86 μM
Compound: JS-K
|
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay relative to control
Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay relative to control
|
[PMID: 29220794] |
| HCT-15 | IC50 |
0.6 μM
Compound: JS-K
|
Antiproliferative activity against human HCT-15 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCT-15 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| HeLa | IC50 |
3.56 μM
Compound: 19
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 25350923] |
| HepG2 | IC50 |
12.2 μM
Compound: JS-K
|
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay
|
[PMID: 23617697] |
| HepG2 | IC50 |
5.19 μM
Compound: JS-K
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 23617697] |
| HepG2 | IC50 |
7.12 μM
Compound: JS-K
|
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay
|
[PMID: 23617697] |
| HepG2 | IC50 |
7.42 μM
Compound: JS-K
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| HL-60 | IC50 |
0.2 μM
Compound: JS-K
|
Antiproliferative activity against human HL-60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL-60 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| HL-60 | IC50 |
0.2 μM
Compound: JS-K
|
Antiproliferative activity against human HL60 cells after 24 hrs
Antiproliferative activity against human HL60 cells after 24 hrs
|
[PMID: 19364650] |
| HL-60 | IC50 |
0.2 μM
Compound: JS-K
|
Antiproliferative activity against human HL60 cells assessed as decrease in cell viability measured after 3 days by MTT assay
Antiproliferative activity against human HL60 cells assessed as decrease in cell viability measured after 3 days by MTT assay
|
[PMID: 28505442] |
| HL-60 | IC50 |
0.2 μM
Compound: JS-K
|
Antileukemic activity in human HL60 cells assessed as nitric oxide release
Antileukemic activity in human HL60 cells assessed as nitric oxide release
|
[PMID: 18178089] |
| HL-60 | IC50 |
0.5 μM
Compound: 2a
|
Antiproliferative activity against human HL60 cell line
Antiproliferative activity against human HL60 cell line
|
[PMID: 16821795] |
| HL-60 | IC50 |
0.53 μM
Compound: 6; JS-K
|
Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
|
[PMID: 32305784] |
| HT-29 | IC50 |
0.8 μM
Compound: JS-K
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| hTERT-BJ | IC50 |
10 μM
Compound: JS-K
|
Antiproliferative activity against human BJ-5ta cells after 72 hrs by MTT assay
Antiproliferative activity against human BJ-5ta cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| HUVEC | IC50 |
5.39 μM
Compound: 19
|
Antiproliferative activity against HUVEC after 48 hrs by MTT assay
Antiproliferative activity against HUVEC after 48 hrs by MTT assay
|
[PMID: 25350923] |
| Jurkat E6.1 | IC50 |
0.92 μM
Compound: JS-K
|
Anticancer activity against human Jurkat E6-1 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
Anticancer activity against human Jurkat E6-1 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
|
[PMID: 32156499] |
| L02 | IC50 |
1.99 μM
Compound: 6; JS-K
|
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay
Cytotoxicity against human HL7702 cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay
|
[PMID: 32305784] |
| MCF-10A | IC50 |
4.91 μM
Compound: JS-K
|
Antiproliferative activity against human MCF10A cells after 48 hrs by MTT assay relative to control
Antiproliferative activity against human MCF10A cells after 48 hrs by MTT assay relative to control
|
[PMID: 29220794] |
| MCF7 | IC50 |
993 nM
Compound: 1; JS-K
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 29420887] |
| MDA-MB-231 | IC50 |
2.9 μM
Compound: 6; JS-K
|
Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay
|
[PMID: 32305784] |
| MDA-MB-231 | IC50 |
5.75 μM
Compound: JS-K
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay relative to control
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay relative to control
|
[PMID: 29220794] |
| MDA-MB-231 | IC50 |
7.93 μM
Compound: JS-K
|
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
Anticancer activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT or MTS assay
|
[PMID: 32156499] |
| NCI-H1373 | IC50 |
0.86 μM
Compound: 1, JS-K
|
Antiproliferative activity against human NCI-H1373 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1373 cells after 72 hrs by MTT assay
|
[PMID: 22003962] |
| NCI-H1703 | IC50 |
0.57 μM
Compound: 1, JS-K
|
Antiproliferative activity against human NCI-H1703 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1703 cells after 72 hrs by MTT assay
|
[PMID: 22003962] |
| NCI-H1703 | IC50 |
1.08 μM
Compound: 1, Js-K
|
Antiproliferative activity against human NCI-H1703 cells after 48 hrs by MTT assay
Antiproliferative activity against human NCI-H1703 cells after 48 hrs by MTT assay
|
[PMID: 22480849] |
| NCI-H1944 | IC50 |
>10 μM
Compound: 1, JS-K
|
Antiproliferative activity against human NCI-H1944 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1944 cells after 72 hrs by MTT assay
|
[PMID: 22003962] |
| NCI-H2122 | IC50 |
3.17 μM
Compound: 1, JS-K
|
Antiproliferative activity against human NCI-H2122 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H2122 cells after 72 hrs by MTT assay
|
[PMID: 22003962] |
| NCI-H441 | IC50 |
0.94 μM
Compound: 1, JS-K
|
Antiproliferative activity against human NCI-H441 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H441 cells after 72 hrs by MTT assay
|
[PMID: 22003962] |
| NCI-H441 | IC50 |
1 μM
Compound: JS-K
|
Antiproliferative activity against human H441 cells after 72 hrs by MTT assay
Antiproliferative activity against human H441 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| NCI-H838 | IC50 |
4.3 μM
Compound: JS-K
|
Antiproliferative activity against human H838 cells after 72 hrs by MTT assay
Antiproliferative activity against human H838 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| OVCAR-3 | IC50 |
>20 μM
Compound: JS-K
|
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 36470106] |
| OVCAR-3 | IC50 |
0.8 μM
Compound: JS-K
|
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human OVCAR-3 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| OVCAR-5 | IC50 |
1 μM
Compound: JS-K
|
Antiproliferative activity against human OVCAR5 cells after 72 hrs by MTT assay
Antiproliferative activity against human OVCAR5 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| Panel NCI-51 (51 carcinoma cell lines) | GI50 |
1.32 μM
Compound: 2a
|
Antiproliferative activity against human NCI51 cell line
Antiproliferative activity against human NCI51 cell line
|
[PMID: 16821795] |
| PC-3 | IC50 |
1.1 μM
Compound: JS-K
|
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| SK-OV-3 | IC50 |
18.5 μM
Compound: JS-K
|
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 36470106] |
| SMMC-7721 | IC50 |
7.31 μM
Compound: JS-K
|
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
Cytotoxicity against human SMMC7721 cells after 72 hrs by MTT assay
|
[PMID: 23617697] |
| SW-620 | IC50 |
5.16 μM
Compound: JS-K
|
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| SW626 | IC50 |
>20 μM
Compound: JS-K
|
Antiproliferative activity against human SW626 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
Antiproliferative activity against human SW626 cells assessed as reduction in cell viability incubated for 24 hrs by CCK8 assay
|
[PMID: 36470106] |
| TK-10 | IC50 |
0.5 μM
Compound: JS-K
|
Antiproliferative activity against human TK-10 cells after 72 hrs by MTT assay
Antiproliferative activity against human TK-10 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| U2OS | IC50 |
6.27 μM
Compound: JS-K
|
Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay relative to control
Antiproliferative activity against human U2OS cells after 48 hrs by MTT assay relative to control
|
[PMID: 29220794] |
| U-937 | IC50 |
0.3 μM
Compound: JS-K
|
Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
Antiproliferative activity against human U937 cells after 72 hrs by MTT assay
|
[PMID: 18930407] |
| U-937 | IC50 |
0.3 μM
Compound: JS-K
|
Antiproliferative activity against human U937 cells after 24 hrs
Antiproliferative activity against human U937 cells after 24 hrs
|
[PMID: 19364650] |
| Vero | IC50 |
1.16 μM
Compound: 6; JS-K
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 96 hrs by Celltiter-Glo assay
|
[PMID: 32305784] |
In Vitro
JS-K (0-5 μM, 3 d) inhibits proliferation of HL-60 (IC50: 0.5 μM), PPC-1, DLD-1, Meth A, U937 (IC50: 0.3 μM) cells[1].
JS-K (0.5 μM, 5 d) leads to HL-60 cells differentiation and acquires some of the phenotypic features of normal monocytes[1].
JS-K (0.5-1 μM, 3 d) induces apoptosis in a concentration and caspase-dependent manner in HL-60 cells[1].
JS-K (12.5-5 μM, 24 h) significantly increases the production of ROS/RNS in a concentration-dependent manner, and the effect is reversed by N-acetyl-L-cysteine (NAC) (HY-B0215) in A2780 and SKOV3 cells[2].
JS-K (12.5-5 μM, 24 h) induces autophagy in A2780 and SKOV3 cells[2].
JS-K (0.5-1 μM, 72 h) inhibits breast cancer invasion across the Matrigel basement membrane, and NO production is vital for this activity. blocking TIMP-2 activity significantly suppressed the anti-invasive effects of JS-K[3].
JS-K (1-10 μM, 24 h) activates apoptosis pathways in Hep3B cells, including induction of caspase-3, caspase-9, Bax, TNF-α, and IL-1β[4].
JS-K (1-10 μM, 24 h) increases thrombospondin-1 (TSP-1) and the metalloproteinase-1 (TIMP-1) at both transcript and protein levels. JS-K increases the expression of differentiation-related genes CD14 and CD11b, and depresses the expression of c-myc[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HL-60
-
Concentration:0.5, 0.75, 1 μM
-
Incubation Time:3 d
-
Result:(0.5, 1 μM) Increased percentage of apoptotic from 7 to 27 and 43%, respectively.
(0.75 μM) Pan-caspase inhibitor CVAD-FMK prevented the growth inhibitory and apoptotic effects.
-
Cell Line:A2780 and SKOV3 cells
-
Concentration:1.25, 2.5, 5 μM
-
Incubation Time:24 h
-
Result:Expression of LC3BII and ATG5 proteins increased, while p62 mRNA level decreased and protein level expression decreased in a concentration-dependent manner.
Induce a greater accumulation of autophagosomes in SKOV3 cells, indicating a disruption in the last step of autophagy in which autophagosomes fuse with lysosomes and the cellular content is degraded.
-
Cell Line:MDA-MB-231, F10, MCF-7/COX-2
-
Concentration:0.5, 1 μM
-
Incubation Time:72 h
-
Result:At the 0.5 and 1 μM doses, the number of invaded cells was decreased 37% and 85% in MDA-MB-231, 63% and 76% in F10, 49% and 75% in MCF-7/COX-2, respectively.
At the 0.5 and 1 μM doses, TIMP-2 levels were increased 1.9-fold and threefold in MDA-MB-231, 1.5-fold and 7.2-fold in F10 cells, respectively. And twofold in MCF-7/COX-2 cells at the 1 μM dose.
In the absence and presence of the anti-TIMP-2 antibody, (1 μM) decreased the number of invaded cells by 72% and 37% in MDA-MB- 231, 72% and 40% in F10, 65% and 30% in MCF-7/COX-2 cells.
-
Cell Line:SKOV3 cells
-
Concentration:2.5 μM
-
Incubation Time:24 h
-
Result:LC3BII, BAX, P62 and Bcl2 proteins were found to be elevated in cells co-treated with BAF.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID mice (6-8 weeks) (injected in the flanks s.c. with HL-60 or PPC-1 cells)[1]
-
Dosage:1.54 mg/kg
-
Administration:Intravenous injection (i.v.), three times/week for 15-20 days
-
Result:Sixteen days after starting therapy, the average tumor volumes in vehicle and experimental group were 8.34 and 3.13 cm3, respectively, reflecting a > 50% reduction in tumor volume in experimental group.
Nineteen days after start of therapy, s.c. tumor implant volumes were 0.368 and 0.107 cm3 in vehicle and experimental group, respectively.
Revealed extensive cell necrosis in HL-60 (> 50%) and PPC-1 cell tumors.
Up to 1.54 mg/kg without observing significant hypotension, whereas doses of 1.54 mg/kg or higher has a notable hypotensive effect.
Chemical Information
-
CAS No. 205432-12-8
-
Appearance Solid
-
Molecular Weight 384.30
-
Formula C13H16N6O8
-
Color White to yellow
-
SMILES
O=C(N1CCN(/[N+]([O-])=N/OC2=CC=C([N+]([O-])=O)C=C2[N+]([O-])=O)CC1)OCC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 36 mg/mL (93.68 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Autophagy
Autophagy is a process in which eukaryotic cells use lysosomes to degrade their own cytoplasmic proteins and damaged organelles under the regulation of autophagy related gene (Atg). Microtubule-associated proteins light chain 3 (LC3) is recognized as autophagy marker, which transfers from cytoplasmic LC3 (LC3-I) to membrane type (LC3-II). LC3-II/I ratio could be detected by Western Blot and fluorescence microscopy.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Macroautophagy Solutions
Macroautophagy is a conserved lysosome-dependent degradation pathway in which cytoplasmic material is sequestered into double-membrane autophagosomes and delivered to lysosomes for degradation and recycling. The pathway supports cellular homeostasis during nutrient limitation, organelle stress, protein-aggregate accumulation, infection, differentiation, and tissue remodeling by coupling cargo sequestration, autophagosome maturation, lysosomal fusion, and degradation of cargo-derived macromolecules. The core molecular sequence includes initiation by nutrient- and stress-regulated autophagy machinery, autophagosome nucleation, LC3/ATG8-family conjugation to autophagosomal membranes, cargo selection through receptors such as SQSTM1/p62, autophagosome-lysosome fusion, and lysosomal degradation. LC3 was identified as a mammalian homolog of yeast Atg8 that localizes to autophagosomal membranes after processing, and p62/SQSTM1 was shown to connect ubiquitinated cargo with autophagic degradati
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Shami PJ, et al. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther. 2003 Apr;2(4):409-17. [Content Brief]
[2]. Liu B, et al. JS-K, a nitric oxide donor, induces autophagy as a complementary mechanism inhibiting ovarian cancer. BMC Cancer. 2019 Jul 1;19(1):645. [Content Brief]
[3]. Simeone AM, et al. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells. Breast Cancer Res. 2008;10(3):R44. [Content Brief]
[4]. Dong R, et al. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells. Biomed Pharmacother. 2017 Apr;88:367-373. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6021 mL | 13.0107 mL | 26.0213 mL | 65.0533 mL |
| 5 mM | 0.5204 mL | 2.6021 mL | 5.2043 mL | 13.0107 mL | |
| 10 mM | 0.2602 mL | 1.3011 mL | 2.6021 mL | 6.5053 mL | |
| 15 mM | 0.1735 mL | 0.8674 mL | 1.7348 mL | 4.3369 mL | |
| 20 mM | 0.1301 mL | 0.6505 mL | 1.3011 mL | 3.2527 mL | |
| 25 mM | 0.1041 mL | 0.5204 mL | 1.0409 mL | 2.6021 mL | |
| 30 mM | 0.0867 mL | 0.4337 mL | 0.8674 mL | 2.1684 mL | |
| 40 mM | 0.0651 mL | 0.3253 mL | 0.6505 mL | 1.6263 mL | |
| 50 mM | 0.0520 mL | 0.2602 mL | 0.5204 mL | 1.3011 mL | |
| 60 mM | 0.0434 mL | 0.2168 mL | 0.4337 mL | 1.0842 mL | |
| 80 mM | 0.0325 mL | 0.1626 mL | 0.3253 mL | 0.8132 mL |